| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 05/07/2002 | US6384062 Pharmaceutical composition |
| 05/07/2002 | US6384016 One peptide selected from glucagon, glp-1, and analogues and derivatives thereof together with a stabilizing and solubilizing amount of at least one detergent, said detergent having at least 2 positive charges, at least 2 negative |
| 05/07/2002 | US6383808 Antisense inhibition of clusterin expression |
| 05/07/2002 | US6383799 Culturing tremella mesenterica in submerged culture on nutrient media, then isolating biomass by alcohol precipitation |
| 05/07/2002 | US6383785 Self-enhancing, pharmacologically controllable expression systems |
| 05/07/2002 | US6383780 2786, a novel human aminopeptidase |
| 05/07/2002 | US6383514 Hypocholesterolemic composition comprising a phytostanol ester and a tocopherol |
| 05/07/2002 | US6383500 Particles comprising amphiphilic copolymers, having a crosslinked shell domain and an interior core domain, useful for pharmaceutical and other applications |
| 05/07/2002 | CA2216535C Protein kinase c inhibitors |
| 05/07/2002 | CA2214884C Poly(hydroxy acid)/polymer conjugates for skin applications |
| 05/02/2002 | WO2002035235A2 Net as regulator of angiogenic expression |
| 05/02/2002 | WO2002034940A2 Methods for screening compounds that modulate lipid metabolism |
| 05/02/2002 | WO2002034904A1 Novel g protein-coupled receptor protein and dna thereof |
| 05/02/2002 | WO2002034903A2 Nucleic acid generating the abca7 gene, molecules modulating its activity and therapeutic applications |
| 05/02/2002 | WO2002034783A2 Transmembrane proteins |
| 05/02/2002 | WO2002034781A1 Human g-protein coupled diadenosine tetraphosphate receptor (ap4ar) |
| 05/02/2002 | WO2002034767A1 Vegf peptides and their use for inhibiting angiogenesis |
| 05/02/2002 | WO2002034753A2 Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034747A1 Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same |
| 05/02/2002 | WO2002034743A1 Triazole derivatives and pharmaceutical compositions comprising them |
| 05/02/2002 | WO2002034741A2 A NOVEL CRYSTALLINE FORM OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL)ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL)BENZO[b]THIOPHENE HYDROCHLORIDE |
| 05/02/2002 | WO2002034726A2 Pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 05/02/2002 | WO2002034718A1 Amide derivatives as nmda receptor antagonists |
| 05/02/2002 | WO2002034716A2 Pyrrolidine modulators of ccr5 chemokine receptor activity |
| 05/02/2002 | WO2002034273A1 Compositions and methods for diagnosis and treatment of cardiovascular disorders |
| 05/02/2002 | WO2002034271A1 New composition and method for the treatment of dysglucaemia |
| 05/02/2002 | WO2002034261A1 Compositions for improving lipids in blood |
| 05/02/2002 | WO2002034259A1 Combination of fenofibrate and coenzyme q10 for the treatment of endothelial dysfunction |
| 05/02/2002 | WO2002034254A1 Nateglinide-containing preparations |
| 05/02/2002 | WO2002034241A2 Compounds comprising a phytosterol and/or phytostanol moiety and ascorbis acid and use thereof as weight regulating agents |
| 05/02/2002 | WO2002034221A1 Dental care compositions |
| 05/02/2002 | WO2002034204A2 Calcilytic compounds |
| 05/02/2002 | WO2002034202A2 Multi-component antioxidant compounds, pharmaceutical compositions containing same and their use for reducing or preventing oxidative stress |
| 05/02/2002 | WO2002034201A2 Use of pericyte apoptosis inhibitors for treating and/or preventing diabetic retinopathy |
| 05/02/2002 | WO2002020525A3 Protein tyrosine phosphatase inhibitor |
| 05/02/2002 | WO2002013800A3 Method for the prevention and treatment of retinopathy |
| 05/02/2002 | WO2002011710A3 Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
| 05/02/2002 | WO2002011564A3 Supplement for type 2 diabetes or lipodystrophy |
| 05/02/2002 | WO2001098330A3 A RECOMBINANT CELL LINE EXPRESSING GPCRx11 AS A FUNCTIONAL RECEPTOR VALIDATED BY ANGIOPEPTIN AND USEFUL FOR SCREENING OF AGONISTS AND ANTAGONISTS |
| 05/02/2002 | WO2001096397A3 Cd154 variants and uses thereof |
| 05/02/2002 | WO2001094586A3 Non-agonistic antibodies to human gp39, compositions containing, and therapeutic use thereof |
| 05/02/2002 | WO2001091803A3 Methods and compounds for controlled release of recombinant parvovirus vectors |
| 05/02/2002 | WO2001081298A3 Cyclic carboxylic acids as integrin antagonists |
| 05/02/2002 | WO2001077137A9 Albumin fusion proteins |
| 05/02/2002 | WO2001062923A3 Transporters and ion channels |
| 05/02/2002 | WO2001062266A3 Use of dpp-iv inhibitors for the treatment of diabetes |
| 05/02/2002 | WO2001061009A3 Polypeptides and nucleic acids encoding same |
| 05/02/2002 | WO2001061008A3 Polypeptides and nucleic acids encoding same |
| 05/02/2002 | WO2001054686A3 L-arginine in combination with other compounds for treating cardiovascular diseases |
| 05/02/2002 | WO2001052829A3 Statin-type bone growth stimulators |
| 05/02/2002 | WO2001049280A3 Weight promoting composition, method, and product |
| 05/02/2002 | WO2001046394A3 Mammalian protein phosphatases |
| 05/02/2002 | WO2001029071A3 Genes associated with obesity and methods for using the same |
| 05/02/2002 | WO2001029070A3 Modulation of t cell differentiation for the treatment of t helper cell mediated diseases |
| 05/02/2002 | WO2001018172A3 Fibroblast growth factor-like polypeptides |
| 05/02/2002 | WO2001009121A3 2-pyrazolin-5-ones_as tyrosine kinase inhibitors |
| 05/02/2002 | WO2000078972A3 Regulation with binding cassette transporter protein abc1 |
| 05/02/2002 | US20020052471 Human procalcitonin and the preparation and use thereof |
| 05/02/2002 | US20020052409 Compounds and methods for treating mitochondria-associated diseases |
| 05/02/2002 | US20020052405 Treating obesity, anxiety disorder, post-traumatic stress disorder, premenstrual syndrome, attention deficit disorder, Tourette syndrome, bulimia nervosa or Shy Drager Syndrome by administering a hydroxycycloalkanephenethyl amine |
| 05/02/2002 | US20020052400 Substituted O- and/or S heterocyclic compounds; powerful ligands for melatoninergic receptors. |
| 05/02/2002 | US20020052398 Pharmaceutical composition of 6-amino EM-12 |
| 05/02/2002 | US20020052397 Treatment of diseases characterized by excess Th2 cytokines and/ or an excess IgE production. |
| 05/02/2002 | US20020052392 Have utility as, inter alia, hypoglycemic, and anti-obesity agents. |
| 05/02/2002 | US20020052387 5-Substituted 2-aryl-4-pyrimidinones |
| 05/02/2002 | US20020052386 Pyrimidine derivatives |
| 05/02/2002 | US20020052383 Phenylcycloalkylmethylamino and phenylalkenylamino derivatives, including 1-phenyl-2-aminomethylcyclopropanes; treatment of a variety of metabolic, feeding, and sexual disorders including obesity. |
| 05/02/2002 | US20020052369 Indolinone derivatives as protein kinase/phosphatase inhibitors |
| 05/02/2002 | US20020052358 Methods and compositions related to modulators of annexin and cartilage homeostasis |
| 05/02/2002 | US20020052356 Quinoline and quinazoline derivatives; prophylaxis or treatment of arthritis, cardiovascular diseases, diabetes, renal failure and particularly eating disorders and obesity. |
| 05/02/2002 | US20020052355 Inhibition of serotonin reuptake; especially 2-(azabicycloalkyl)alkylenyl)isoquinolin-3-one compounds |
| 05/02/2002 | US20020052350 1alpha-hydroxy-2-methylene-19-nor-homopregnacalciferol and its uses |
| 05/02/2002 | US20020052349 p-(sulfonyl) aryl and heteroarylamines as anti-inflammatory agents |
| 05/02/2002 | US20020052348 Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase |
| 05/02/2002 | US20020052347 Protein tyrosine phosphatase 1B (PTP-1B) inhibitors containing two ortho-substituted aromatic phosphonates |
| 05/02/2002 | US20020052346 Phosphonic acid biaryl derivatives as inhibitors of protein tyrosine phosphatase 1B (PTP-1B) |
| 05/02/2002 | US20020052344 Phosphonic acid derivatives as inhibitors of protein tyrosine phosphatase IB (PTP-IB) |
| 05/02/2002 | US20020052326 Treating diabetes and related diseases in combination with one, two or more other antidiabetic agents and/or one, two or more hypolipidemic agents. |
| 05/02/2002 | US20020052325 E.g., topiramate |
| 05/02/2002 | US20020052315 Conformationally constrained backbone cyclized somatostatin analogs |
| 05/02/2002 | US20020051828 Mixtures which can be isolated from eugenia jambolana lamarck seeds, their preparation and the use of these mixtures and some of their constituents as medicaments |
| 05/02/2002 | US20020051771 Apoptotic entities for use in treatment of T-cell-mediated and inflammatory disorders |
| 05/02/2002 | US20020050276 Method and bottle for infant feeding |
| 05/02/2002 | EP1202065A1 Net, a transcription factor of the TCF family, as regulator of angiogenic expression. |
| 05/02/2002 | EP1201664A1 Benzimidazole compounds and drugs containing the same |
| 05/02/2002 | EP1201660A1 Glucocorticoid receptor modulators |
| 05/02/2002 | EP1201649A1 Glucocorticoid receptor modulators |
| 05/02/2002 | EP1201237A1 Composition comprising an amide or a dialkylsulphoxide derivative for the treatment of cancer |
| 05/02/2002 | EP1201231A2 Suspension or particle-solvent mixture system of zinc-containing calcium phosphate microparticle, and therapeutic agent for treating zinc deficiency |
| 05/02/2002 | EP1201136A1 Food grade transglutaminase inhibitor and uses thereof |
| 05/02/2002 | EP1200835A1 Methods for identification of compounds stimulating insulin secretion |
| 05/02/2002 | EP1200831A1 Modulating binding site on potassium channels used for screening |
| 05/02/2002 | EP1200602A1 Dsp-11 dual-specificity map kinase phophatase |
| 05/02/2002 | EP1200595A2 Myxoma virus genes for immune modulation |
| 05/02/2002 | EP1200593A2 The il-1l1 gene and polypeptide products |
| 05/02/2002 | EP1200591A1 Human homologue of bovine neuroendocrine secretory protein, nesp55, polynucleotides and uses thereof linked with obesity |
| 05/02/2002 | EP1200589A1 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 05/02/2002 | EP1200587A2 Receptors and associated proteins |
| 05/02/2002 | EP1200582A2 Human proteins having hydrophobic domains and dnas encoding these proteins |
| 05/02/2002 | EP1200572A1 Antisense modulation of liver glycogen phosphorylase expression |